drugset
drugset / Trial / NCT06037317

A Study of SY-3505 in Patients With Advanced LTK Fusion-Positive Solid Tumors

NCT06037317 ↗

Phase 1 Unknown 38 enrolled Shouyao Holdings (Beijing) Co. LTD
NaSingle-groupOpen-labelTreatment

Summary

This is an open-label, single-arm, multicenter, phase Ib study to evaluate the efficacy and safety of SY-3505 capsule in patients with locally advanced or metastatic, LTK fusion-positive solid tumor who have progressed on or are intolerant to prior standard therapy.

Timeline

Start
2024-05-30
Primary completion
2025-12-30
Completion
2026-05-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Ficonalkib Small molecule 500 mg Oral
Subject Ficonalkib Small molecule 600 mg Oral
Subject Ficonalkib Small molecule 800 mg Oral

Indications

neoplasm